HemaSphere (Jun 2022)

P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA

  • M. K. Leabman,
  • G. Hernandez,
  • C. M. Ng,
  • J. Tang,
  • D. Pandya,
  • K. C. Hart,
  • K. Li,
  • P. R. Hinton,
  • J. So,
  • I. Qazi,
  • C. Y. Cheah,
  • W. S. Kim,
  • E. Budde,
  • A. K. Gopal,
  • T. Manley,
  • C. H. Takimoto,
  • A. M. Sinclair,
  • S. F. Carroll,
  • B. A. Keyt,
  • M. F. Kotturi

DOI
https://doi.org/10.1097/01.HS9.0000847968.95263.25
Journal volume & issue
Vol. 6
pp. 1161 – 1162

Abstract

Read online

No abstracts available.